Endologix (ELGX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-129.75M
Depreciation and amortization	6.57M
Stock-based compensation	9.64M
Change in fair value of contingent consideration related to acquisition related to acquisition (Note 10)
Gain on sale of equipment
Accounts receivable	-3.88M
Other receivables
Inventories	2.08M
Prepaid expenses and other current assets	535K
Accounts payable	-6.61M
Accrued payroll	7.66M
Accrued expenses and other liabilities	3.5M
Net cash used in operating activities	-60.07M
Purchases of property and equipment	-2.05M
Net cash used in investing activities	-45.8M
Proceeds from sale of common stock under employee stock purchase plan	2.52M
Proceeds from exercise of stock options	1.78M
Repayments of long-term debt
Net cash provided by financing activities	3.25M
Net decrease in cash and cash equivalents	-102.53M
Cash and cash equivalents, beginning of period	124.55M
Cash and cash equivalents, end of period	22.02M

Entities mentioned with ELGX

View All Entities